Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 03 2019 - 10:30AM
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a
cutting-edge biotechnology company developing new treatments for
life-threatening medical conditions by improving the body’s ability
to bring oxygen to the areas where it is needed most, today
announced that management will present at the H.C. Wainwright 21st
Annual Global Investment Conference on Monday, September 9, 2019 at
4:40 p.m. Eastern Time. The conference will be held September 8-10
at the Lotte New York Palace Hotel in New York City.
To listen to the presentation live, investors
may visit the Investor Relations section of Diffusion
Pharmaceuticals’ website at www.diffusionpharma.com. An archived
webcast of the presentation will also be available on the Company’s
website for a period of time.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biotechnology company developing new treatments that improve the
body’s ability to bring oxygen to the areas where it is needed
most, offering new hope for the treatment of life-threatening
medical conditions.
Diffusion’s lead drug TSC was originally
developed in conjunction with the Office of Naval Research, which
was seeking a way to treat hemorrhagic shock caused by massive
blood loss on the battlefield.
Evolutions in research have led to Diffusion’s
focus today: Fueling Life by taking on some of medicine’s most
intractable and difficult-to-treat diseases, including stroke and
GBM brain cancer. In each of these diseases, hypoxia – oxygen
deprivation of essential tissue in the body – has proved to be a
significant obstacle for medical providers and the target for TSC’s
novel mechanism.
Its on-ambulance PHAST-TSC acute stroke protocol
has been granted FDA clearance to proceed and the Company plans to
enroll patients in this Phase 2 study in the third quarter 2019. In
July 2019 the Company reported favorable safety data in a
19-patient dose-escalation run-in study to its Phase 3 INTACT
program, using TSC to target inoperable GBM brain cancer.
Additional preclinical data supports the potential use of TSC
as a treatment for other conditions where hypoxia plays a major
role, such as myocardial infarction, respiratory diseases such as
COPD, peripheral artery disease, and neurodegenerative conditions
such as Alzheimer’s and Parkinson’s disease.
In addition, RES-529, the Company’s
PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and
mTORC2 complexes, is in preclinical testing for GBM.
Diffusion is headquartered in Charlottesville,
Virginia – a hub of advancement in the life science and
biopharmaceutical industries – and is led by CEO David Kalergis, a
30-year industry veteran and company co-founder.
Contacts:David Kalergis,
CEODiffusion Pharmaceuticals Inc.(434)
220-0718dkalergis@diffusionpharma.com
LHA Investor RelationsKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Sep 2023 to Sep 2024